In this issue:
The European IPF Patient Charter
End-of-life care in oxygen-dependent ILD vs. lung cancer
Multidisciplinary team agreement of diffuse parenchymal lung disease diagnosis
Antacids don’t improve IPF outcomes
Corticosteroids reduce muscle strength in ILD
Acetylcysteine added to pirfenidone not beneficial in IPF
Clinical, radiological and histological features of LD-CTD
Predictors of mortality in RA-associated ILD
Erroneous ordering of ACE level tests in ACE inhibitor recipients
Pulmonary hypertension in IPF with mild-to-moderate restriction
Hypersensitivity pneumonitis with a UIP-like pattern
Noninfectious ILD after stem-cell transplant in paediatric cancer patients
Please login below to download this issue (PDF)